Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial.

Stewart KD, Matza LS, Chinthammit C, Pavo I, Bartee AK, Boye KS

Diabetes therapy : research, treatment and education of diabetes and related disorders17 Sept 2026

PMID42754765DOI10.1007/s13300-026-01907-yPepBankPUB-42754765

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study24

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone24

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
Among pooled dulaglutide and tirzepatide interviewees with diabetes, 97.3% reported improved glycemic control.
In plain wordsAmong pooled dulaglutide and tirzepatide interviewees with diabetes, 97.3% reported better blood sugar control.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseReported glycemic control improvement
Study
n = 74
Outcome group
Glycemic control · Metabolic and weight
Measurements
Reported improved glycemic control
97.3%
pooled dulaglutide and tirzepatide interviewees
Source sentences
Summary
Participants reported treatment benefits during the trial, such as improved glycemic control (97.3%), weight reduction (91.9%), reduced appetite (78.4%), improved diet and eating habits (64.9%), increased energy (56.8%), and decreased desire for unhealthy food (41.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4275476501
02HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
Among pooled dulaglutide and tirzepatide interviewees with diabetes, 97.3% reported improved glycemic control.
In plain wordsAmong pooled dulaglutide and tirzepatide interviewees with diabetes, 97.3% reported better blood sugar control.
Peptide
Tirzepatide
Outcome
IncreaseReported glycemic control improvement
Study
n = 74
Outcome group
Glycemic control · Metabolic and weight
Measurements
Reported improved glycemic control
97.3%
pooled dulaglutide and tirzepatide interviewees
Source sentences
Summary
Participants reported treatment benefits during the trial, such as improved glycemic control (97.3%), weight reduction (91.9%), reduced appetite (78.4%), improved diet and eating habits (64.9%), increased energy (56.8%), and decreased desire for unhealthy food (41.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4275476502
03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
Among pooled dulaglutide and tirzepatide interviewees with diabetes, 91.9% reported weight reduction.
In plain wordsAmong pooled dulaglutide and tirzepatide interviewees with diabetes, 91.9% reported weight loss.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseReported weight reduction
Study
n = 74
Outcome group
Body weight · Metabolic and weight
Measurements
Reported weight reduction
91.9%
pooled dulaglutide and tirzepatide interviewees
Source sentences
Summary
Participants reported treatment benefits during the trial, such as improved glycemic control (97.3%), weight reduction (91.9%), reduced appetite (78.4%), improved diet and eating habits (64.9%), increased energy (56.8%), and decreased desire for unhealthy food (41.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4275476503
04HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
Among pooled dulaglutide and tirzepatide interviewees with diabetes, 91.9% reported weight reduction.
In plain wordsAmong pooled dulaglutide and tirzepatide interviewees with diabetes, 91.9% reported weight loss.
Peptide
Tirzepatide
Outcome
DecreaseReported weight reduction
Study
n = 74
Outcome group
Body weight · Metabolic and weight
Measurements
Reported weight reduction
91.9%
pooled dulaglutide and tirzepatide interviewees
Source sentences
Summary
Participants reported treatment benefits during the trial, such as improved glycemic control (97.3%), weight reduction (91.9%), reduced appetite (78.4%), improved diet and eating habits (64.9%), increased energy (56.8%), and decreased desire for unhealthy food (41.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4275476504
05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
Among pooled dulaglutide and tirzepatide interviewees with diabetes, 78.4% reported reduced appetite.
In plain wordsAmong pooled dulaglutide and tirzepatide interviewees with diabetes, 78.4% reported less appetite.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseReported appetite reduction
Study
n = 74
Outcome group
Appetite and food intake · Metabolic and weight
Measurements
Reported reduced appetite
78.4%
pooled dulaglutide and tirzepatide interviewees
Source sentences
Summary
Participants reported treatment benefits during the trial, such as improved glycemic control (97.3%), weight reduction (91.9%), reduced appetite (78.4%), improved diet and eating habits (64.9%), increased energy (56.8%), and decreased desire for unhealthy food (41.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4275476505
06HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
Among pooled dulaglutide and tirzepatide interviewees with diabetes, 78.4% reported reduced appetite.
In plain wordsAmong pooled dulaglutide and tirzepatide interviewees with diabetes, 78.4% reported less appetite.
Peptide
Tirzepatide
Outcome
DecreaseReported appetite reduction
Study
n = 74
Outcome group
Appetite and food intake · Metabolic and weight
Measurements
Reported reduced appetite
78.4%
pooled dulaglutide and tirzepatide interviewees
Source sentences
Summary
Participants reported treatment benefits during the trial, such as improved glycemic control (97.3%), weight reduction (91.9%), reduced appetite (78.4%), improved diet and eating habits (64.9%), increased energy (56.8%), and decreased desire for unhealthy food (41.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4275476506
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
Among pooled dulaglutide and tirzepatide interviewees with diabetes, 64.9% reported improved diet and eating habits.
In plain wordsAmong pooled dulaglutide and tirzepatide interviewees with diabetes, 64.9% reported better diet and eating habits.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseReported diet improvement
Study
n = 74
Outcome group
Appetite and food intake · Metabolic and weight
Measurements
Reported improved diet and eating habits
64.9%
pooled dulaglutide and tirzepatide interviewees
Source sentences
Summary
Participants reported treatment benefits during the trial, such as improved glycemic control (97.3%), weight reduction (91.9%), reduced appetite (78.4%), improved diet and eating habits (64.9%), increased energy (56.8%), and decreased desire for unhealthy food (41.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4275476507
08HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
Among pooled dulaglutide and tirzepatide interviewees with diabetes, 64.9% reported improved diet and eating habits.
In plain wordsAmong pooled dulaglutide and tirzepatide interviewees with diabetes, 64.9% reported better diet and eating habits.
Peptide
Tirzepatide
Outcome
IncreaseReported diet improvement
Study
n = 74
Outcome group
Appetite and food intake · Metabolic and weight
Measurements
Reported improved diet and eating habits
64.9%
pooled dulaglutide and tirzepatide interviewees
Source sentences
Summary
Participants reported treatment benefits during the trial, such as improved glycemic control (97.3%), weight reduction (91.9%), reduced appetite (78.4%), improved diet and eating habits (64.9%), increased energy (56.8%), and decreased desire for unhealthy food (41.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4275476508
09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
Among pooled dulaglutide and tirzepatide interviewees with diabetes, 56.8% reported increased energy.
In plain wordsAmong pooled dulaglutide and tirzepatide interviewees with diabetes, 56.8% reported more energy.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseReported energy increase
Study
n = 74
Outcome group
Exercise and physical function · Whole body
Measurements
Reported increased energy
56.8%
pooled dulaglutide and tirzepatide interviewees
Source sentences
Summary
Participants reported treatment benefits during the trial, such as improved glycemic control (97.3%), weight reduction (91.9%), reduced appetite (78.4%), improved diet and eating habits (64.9%), increased energy (56.8%), and decreased desire for unhealthy food (41.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4275476509
10HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
Among pooled dulaglutide and tirzepatide interviewees with diabetes, 56.8% reported increased energy.
In plain wordsAmong pooled dulaglutide and tirzepatide interviewees with diabetes, 56.8% reported more energy.
Peptide
Tirzepatide
Outcome
IncreaseReported energy increase
Study
n = 74
Outcome group
Exercise and physical function · Whole body
Measurements
Reported increased energy
56.8%
pooled dulaglutide and tirzepatide interviewees
Source sentences
Summary
Participants reported treatment benefits during the trial, such as improved glycemic control (97.3%), weight reduction (91.9%), reduced appetite (78.4%), improved diet and eating habits (64.9%), increased energy (56.8%), and decreased desire for unhealthy food (41.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4275476510
11HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
Among pooled dulaglutide and tirzepatide interviewees with diabetes, 41.9% reported decreased desire for unhealthy food.
In plain wordsAmong pooled dulaglutide and tirzepatide interviewees with diabetes, 41.9% reported less desire for unhealthy food.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDesire for unhealthy food
Study
n = 74
Outcome group
Appetite and food intake · Metabolic and weight
Measurements
Reported decreased desire for unhealthy food
41.9%
pooled dulaglutide and tirzepatide interviewees
Source sentences
Summary
Participants reported treatment benefits during the trial, such as improved glycemic control (97.3%), weight reduction (91.9%), reduced appetite (78.4%), improved diet and eating habits (64.9%), increased energy (56.8%), and decreased desire for unhealthy food (41.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4275476511
12HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
Among pooled dulaglutide and tirzepatide interviewees with diabetes, 41.9% reported decreased desire for unhealthy food.
In plain wordsAmong pooled dulaglutide and tirzepatide interviewees with diabetes, 41.9% reported less desire for unhealthy food.
Peptide
Tirzepatide
Outcome
DecreaseDesire for unhealthy food
Study
n = 74
Outcome group
Appetite and food intake · Metabolic and weight
Measurements
Reported decreased desire for unhealthy food
41.9%
pooled dulaglutide and tirzepatide interviewees
Source sentences
Summary
Participants reported treatment benefits during the trial, such as improved glycemic control (97.3%), weight reduction (91.9%), reduced appetite (78.4%), improved diet and eating habits (64.9%), increased energy (56.8%), and decreased desire for unhealthy food (41.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4275476512
13HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
Among pooled dulaglutide and tirzepatide interviewees, 18.9% reported improvement in joint pain or osteoarthritis.
In plain wordsAmong pooled dulaglutide and tirzepatide interviewees, 18.9% reported better joint pain or osteoarthritis.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseJoint pain or osteoarthritis improvement
Study
n = 74
Outcome group
Bone and joint · Musculoskeletal
Measurements
Reported improvement in joint pain or osteoarthritis
18.9%
pooled dulaglutide and tirzepatide interviewees
Source sentences
Summary
Some also noted improvement in conditions other than T2D, including joint pain/osteoarthritis (18.9%) and sleep apnea (8.1%).
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4275476513
14HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
Among pooled dulaglutide and tirzepatide interviewees, 18.9% reported improvement in joint pain or osteoarthritis.
In plain wordsAmong pooled dulaglutide and tirzepatide interviewees, 18.9% reported better joint pain or osteoarthritis.
Peptide
Tirzepatide
Outcome
DecreaseJoint pain or osteoarthritis improvement
Study
n = 74
Outcome group
Bone and joint · Musculoskeletal
Measurements
Reported improvement in joint pain or osteoarthritis
18.9%
pooled dulaglutide and tirzepatide interviewees
Source sentences
Summary
Some also noted improvement in conditions other than T2D, including joint pain/osteoarthritis (18.9%) and sleep apnea (8.1%).
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4275476514
15HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
Among pooled dulaglutide and tirzepatide interviewees, 8.1% reported improved sleep apnea.
In plain wordsAmong pooled dulaglutide and tirzepatide interviewees, 8.1% reported better sleep apnea.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseSleep apnea improvement
Study
n = 74
Outcome group
Sleep · Sleep
Measurements
Reported improvement in sleep apnea
8.1%
pooled dulaglutide and tirzepatide interviewees
Source sentences
Summary
Some also noted improvement in conditions other than T2D, including joint pain/osteoarthritis (18.9%) and sleep apnea (8.1%).
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4275476515
16HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
Among pooled dulaglutide and tirzepatide interviewees, 8.1% reported improved sleep apnea.
In plain wordsAmong pooled dulaglutide and tirzepatide interviewees, 8.1% reported better sleep apnea.
Peptide
Tirzepatide
Outcome
DecreaseSleep apnea improvement
Study
n = 74
Outcome group
Sleep · Sleep
Measurements
Reported improvement in sleep apnea
8.1%
pooled dulaglutide and tirzepatide interviewees
Source sentences
Summary
Some also noted improvement in conditions other than T2D, including joint pain/osteoarthritis (18.9%) and sleep apnea (8.1%).
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4275476516
17HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Nearly all pooled dulaglutide and tirzepatide interviewees considered their reported treatment-related changes meaningful.
In plain wordsNearly all pooled dulaglutide and tirzepatide interviewees considered the reported treatment changes meaningful.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableMeaningfulness of changes
Study
n = 74
Outcome group
Patient-reported outcomes · Whole body
Source sentences
Summary
Nearly all participants said these treatment-related changes were meaningful.
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4275476517
18HumanNot a test of Tirzepatide aloneObservational studyOther
Nearly all pooled dulaglutide and tirzepatide interviewees considered their reported treatment-related changes meaningful.
In plain wordsNearly all pooled dulaglutide and tirzepatide interviewees considered the reported treatment changes meaningful.
Peptide
Tirzepatide
Outcome
Not applicableMeaningfulness of changes
Study
n = 74
Outcome group
Patient-reported outcomes · Whole body
Source sentences
Summary
Nearly all participants said these treatment-related changes were meaningful.
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4275476518
19HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
Pooled dulaglutide and tirzepatide interviewees described treatment-associated improvements in quality of life and daily activities.
In plain wordsPooled dulaglutide and tirzepatide interviewees reported better quality of life and daily activities with treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseQuality of life and daily activities
Study
n = 74
Outcome group
Quality of life · Whole body
Source sentences
Summary
Participants described improvements in quality of life and daily activities associated with treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4275476519
20HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
Pooled dulaglutide and tirzepatide interviewees described treatment-associated improvements in quality of life and daily activities.
In plain wordsPooled dulaglutide and tirzepatide interviewees reported better quality of life and daily activities with treatment.
Peptide
Tirzepatide
Outcome
IncreaseQuality of life and daily activities
Study
n = 74
Outcome group
Quality of life · Whole body
Source sentences
Summary
Participants described improvements in quality of life and daily activities associated with treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4275476520
21HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
Among pooled dulaglutide and tirzepatide interviewees, nausea was the most commonly reported adverse event at 28.4%.
In plain wordsAmong pooled dulaglutide and tirzepatide interviewees, 28.4% reported nausea, the most common reported side effect.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableNausea
Study
n = 74
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Reported nausea
28.4%
pooled dulaglutide and tirzepatide interviewees
Source sentences
Summary
The most commonly reported adverse event was nausea (28.4%).
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4275476522
22HumanNot a test of Tirzepatide aloneObservational studySafety outcome
Among pooled dulaglutide and tirzepatide interviewees, nausea was the most commonly reported adverse event at 28.4%.
In plain wordsAmong pooled dulaglutide and tirzepatide interviewees, 28.4% reported nausea, the most common reported side effect.
Peptide
Tirzepatide
Outcome
Not applicableNausea
Study
n = 74
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Reported nausea
28.4%
pooled dulaglutide and tirzepatide interviewees
Source sentences
Summary
The most commonly reported adverse event was nausea (28.4%).
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4275476523
23HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Among pooled dulaglutide and tirzepatide interviewees, 77.0% were very likely and 16.2% likely to recommend treatment.
In plain wordsAmong pooled dulaglutide and tirzepatide interviewees, 77.0% were very likely and 16.2% likely to recommend treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableWillingness to recommend treatment
Study
n = 74
Outcome group
Patient-reported outcomes · Whole body
Measurements
Very likely to recommend treatment
77%
pooled dulaglutide and tirzepatide interviewees
Likely to recommend treatment
16.2%
pooled dulaglutide and tirzepatide interviewees
Source sentences
Summary
Most participants said they would be very likely (77.0%) or likely (16.2%) to recommend their treatment to others.
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4275476524
24HumanNot a test of Tirzepatide aloneObservational studyOther
Among pooled dulaglutide and tirzepatide interviewees, 77.0% were very likely and 16.2% likely to recommend treatment.
In plain wordsAmong pooled dulaglutide and tirzepatide interviewees, 77.0% were very likely and 16.2% likely to recommend treatment.
Peptide
Tirzepatide
Outcome
Not applicableWillingness to recommend treatment
Study
n = 74
Outcome group
Patient-reported outcomes · Whole body
Measurements
Very likely to recommend treatment
77%
pooled dulaglutide and tirzepatide interviewees
Likely to recommend treatment
16.2%
pooled dulaglutide and tirzepatide interviewees
Source sentences
Summary
Most participants said they would be very likely (77.0%) or likely (16.2%) to recommend their treatment to others.
3 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this exit interview study was to examine the impact of long-term treatment with dulaglutide and tirzepatide from the perspective of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.
Summary · context
Interviews were conducted after participants completed treatment with either dulaglutide or tirzepatide in the multiyear SURPASS-CVOT clinical trial.
Summary · context
A total of 74 participants were interviewed (63.5% male; mean age = 68.9 years), including 31 treated with dulaglutide and 43 treated with tirzepatide.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4275476525

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.